Fudan University Shanghai Cancer Center

—A Brief Introduction, 2023

Fudan University Shanghai Cancer Center (FUSCC) is one of the budget management hospitals under National Health Commission of the People’s Republic of China. Established on March 1, 1931 as the earliest specialized cancer institution in China, FUSCC has now developed to be a grade-A tertiary hospital engaged in the integration of clinical practice, medical education, oncologic research and cancer prevention.

The Basic Information 

Geographically, FUSCC consists of two parts, one in Xuhui District and the other in Pudong New Area, called Shanghai Proton and Heavy Ion Hospital; they are highly merged with each other. FUSCC has been honorably authorized to jointly construct Fujian Hospital with Xiamen Municipal Government as a state-regional medical center, and Minhang Extension with Minhang District Government, for the sake of common development of homogenization.

At present, FUSCC spares no effort to build itself to be National Cancer Medical Center, with a view to bolstering its high quality development. Thanks to this, FUSCC has been municipally approved as a pilot unit of tutorship for the Hi-Q development of state-run hospitals in Shanghai.   

As of the end of 2023, FUSCC had 2,149 sick beds available and 43 clinical and technical departments in operation, with a total number of 2,979 staff members. 

The Discipline Platform 

FUSCC has been heavily engaged in the construction of discipline platforms: two key disciplines under Ministry of Education, six state-level clinical key specialties, three key clinical disciplines under Ministry of Health and one innovative team under Ministry of Education. Municipally, FUSCC is equipped with Shanghai Clinical Medicine Center, clinical key disciplines of priority and clinical key specialties. 

FUSCC is affiliated with Shanghai Pathology and Radiotherapy Quality Control Center, and an assisted unit of Shanghai Anti-cancer Association. FUSCC is also equipped with a national drug clinical trial agency, three Shanghai key laboratories on breast cancer, pancreatic cancer and radiation oncology and Shanghai Pathological Diagnosis Clinical Medical Research Center. Moreover, two workstations have been set up in the Name of Academician WANG Hongyang and Academician TIAN Zhigang. Additionally, Precision Oncology Center and Cell and Gene Therapy Center have been successfully constructed, plus the completion of the project to improve diagnosis and therapeutic capacity of difficult diseases.

The Medical Business 

In 2023, FUSCC hit a high record of 2,021,600 outpatient visits, 163,800 inpatient hospitalizations, and 71,000 surgeries, respectively. Meanwhile, Shanghai Proton and Heavy Ion Hospital reached a high record of 1,090 patients treated and discharged, an addition to the accumulation of 6,395 cases since it was put into operation. 

Maintaining a deep commitment to the patient-centered notion and the principle of public welfare, FUSCC has made double effort to substantialize multidisciplinary outpatient service and inpatient care, precision oncotherapy, minimally invasive surgery, and whole-process patient management, as manifested by the construction of single disease comprehensive diagnosis and treatment center, the digital transformation of healthcare, the building of intelligent hospital, day surgery and radiotherapy, etc. As a result, significant progresses have been made in the total quality improvement and overall patient satisfaction. According to the latest statistics, FUSCC has had the five-year survival rate reach 71.6%, which tops other counterparts across the country and is on the same level with that in the developed countries,

The Oncologic Expertise  

 FUSCC sticks to the strategy of building up itself with expertise personnel. Laudably, FUSCC has had thirty-seven individuals recognized and authorized nationally with different titles for their achievements and accomplishments in oncology. Approximately, a number of seventy accomplished experts and specialists have concurrently served as vice chair, co-chair and executive for different associations and institutions. Equipped with the highly recognized expertise personnel, FUSCC heads up the development of oncology in China. 

In oncologic training, FUSCC offers eight state-level discipline bases for residents, eight city-level discipline bases for oncologic specialists, which annually turns out quite a number of young and promising individuals with oncologic expertise.  

The Research Innovation 

FUSCC never stops building itself to be a research-based hospital. In 2023, FUSCC won a number of eighty-nine newly approved research projects funded by National Natural Science Foundation of China, of which especially there were four priorities.  

In documentation, FUSCC had twelve research papers published in the journals of IF≥20, winning fourteen prizes and awards in 2023. By bolstering the industry-university-research medical cooperation, FUSCC succeeded in accomplishing the total amount of RMB41,600,000.00 for achievement transformation. In promoting clinical researches, FUSCC was entitled to 424 newly approved clinical researches, heading up 292 of them domestically and 21 of them internationally (multi-centered). Additionally, FUSCC was authorized to build demonstrative research-based wards. 

With an accumulation of over eighty modifications in the international guidelines in oncology, FUSCC has had its academic voice heard and wisdom appreciated in the world. 

The Practice of the Basic Mission 

In response to the national strategic deployment, FUSCC has been dedicating itself to the practice of a public hospital, maintaining a deep commitment to the basic mission: To Care for the Patient, as manifested in the on-going effort to build itself to be a national civilized working unit with advanced hospital culture. Furthermore, FUSCC has been actively engaged in the network construction of oncologic prevention and treatment at three levels so that it has coordinated the construction of oncologic consortium which has involved approximately one hundred member units. 

FUSCC plays an active role in delivering medical assistance to Xizang, Xinjiang, Yunnan and internationally to Morocco, its laudable medical service being highly recognized.

Meanwhile, FUSCC spares no effort to promote international co-operations and bilateral exchanges; so far it has signed framework cooperation agreements with over ten well-known institutions including MD Anderson Cancer Center in U.S.A. 

FUSCC pledges to continue its effort in response to the national strategy of health and well-being, advancing its high quality development and stretching itself towards the construction fulfillment of National Cancer Medical Center to benefit the city of Shanghai and the whole country as well.